| Catalyst | Drug/Treatment | Stage | Probability of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
PDUFA Date example | PDUFA | — | Subscribe to access the data. | Small Molecules | Rare Diseases | ||
PDUFA Date example | PDUFA | — | Subscribe to access the data. | Small Molecules | Rare Diseases | ||
PDUFA Date example | PDUFA | — | Subscribe to access the data. | Small Molecules | Rare Diseases |
Recent Updates
Recently added Catalysts
Mirum Pharmaceuticals, Inc.$122.13
-5.2 (-4.07%)
C 49Pipeline Score Overvalued Pharma · Commercial
Market Cap
6.01 B
EPS
-13.60
P/E Ratio
-
Value Trade
56.90 M
SEC Financials
Q1 2026Dilution Risk
Revenue
159.88 M
R&D Expenses
97.91 M
Operating CF
-228.76 M
Total Assets
890.92 M
Total Liabilities
648.42 M
Equity
242.49 M
D/E Ratio
12,345
-9.91 %
Week
5.51 %
1 Month
-6.36 %
3 Month
42.14 %
6 Month
458.44 %
5 Year
658.62 %
All Time
Cash Data
Cash Position
386.26 M
Monthly Burn
76.25 M
Runway
3.2 mo
Burn Trend
SEC Filing
May 6, 2026
Overview
Volume
539.11 K
52 Week Range
43.30 - 114.99
% held by Insiders
18.52 %
% held by Institutions
95.45 %
Enterprise Value
5.95 B
Total Shares
60.33 M
Short %
15.33 %
Float Shares
48.80 M
Company Description
locked
Upcoming Catalyst
Catalyst Timeline
Dated clinical, regulatory & corporate events for Mirum Pharmaceuticals, Inc.
284Total events
9Upcoming
115Tier-1 (high impact)
2019 – 2027Coverage
Upcoming catalysts 9
Event history 275
Q3 2026
◆Topline ReadoutBrelovitugClinical Data
Topline Phase 3 results expected in 2H 2026
chronic hepatitis delta virus (HDV)source ↗
Jun 14, 2026
▲Topline ReadoutzilurgisertibClinical Data
Positive pivotal Phase 2 results from PROGRESS study of Zilurgisertib in FOP
Fibrodysplasia Ossificans Progressivasource ↗
Jun 1, 2026
▲Oral PresentationVolixibatPresentation
Late-breaking VISTAS results presented at EASL 2026
primary sclerosing cholangitis (PSC)source ↗
Jun 1, 2026
▲Oral PresentationBrelovitugPresentation
Late-breaking Phase 2b AZURE-1 results presented at EASL 2026
chronic hepatitis delta virus (HDV)source ↗
Jun 1, 2026
▲Oral PresentationLIVMARLIApprovedPresentation
LIVMARLI data on event-free survival in PFIC presented at EASL 2026
progressive familial intrahepatic cholestasis (PFIC)source ↗
May 30, 2026
◆Oral PresentationVolixibatPresentation
Volixibat VISTAS full results late-breaking oral presentation at EASL
primary sclerosing cholangitis (PSC)source ↗
May 27, 2026
◆Poster PresentationBrelovitugPresentation
Brelovitug AZURE-1 full results late-breaking poster at EASL
chronic hepatitis delta virus (HDV)source ↗
May 6, 2026
▲Primary Endpoint MetVolixibatClinical Data
Volixibat VISTAS Phase 2b met primary endpoint
primary sclerosing cholangitis (PSC)source ↗
May 6, 2026
▲Primary Endpoint MetBrelovitugClinical Data
Brelovitug Phase 2b portion of AZURE-1 met primary endpoint
chronic hepatitis delta virus (HDV)source ↗
Drug Pipeline Intelligence
C49
Pipeline Score $1.1B
Pipeline ValueOvervalued
Valuation Signal9
Drugs Scored0.6x
rNPV / MCap Top 73%
Small Cap (rank 247 of 911)
Percentile RankMirum Pharmaceuticals, Inc. carries a moderate pipeline score (49/100), with $3.4B risk-adjusted pipeline value, led by Blinded CDCA in CTX (Phase 3), but cash runway is a concern.
Showing 1 of 1 assets
| Drug | Indication | Phase | NCT ID | PTRS | rNPV | Status | Enrollment | Velocity | Design | Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Blinded CDCA Small molecule | CTX | Phase 3 | NCT04270682 | 50% | $1.7B | COMPLETED | 19 | - | - | Oct 4, 2023 | - | Oct 28, 2024 |
Clinical Trial Results
| Drug Name | Indications | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
volixibat | primary sclerosing cholangitis (PSC) | Phase 2b | 2026-06-01 | rapid, sustained, and clinically meaningful reductions in pruritus Read More | Mirum Pharmaceuticals Announces New Data from Rare Liver Disease Programs Presented at the EASL International Liver Congress 2026 Read More | |
volixibat | primary sclerosing cholangitis (PSC) | Phase 2b | 2026-06-01 | rapid, sustained, and clinically meaningful reductions in pruritus Read More | Mirum Pharmaceuticals Announces New Data from Rare Liver Disease Programs Presented at the EASL International Liver Congress 2026 Read More | |
volixibat | primary sclerosing cholangitis (PSC) | Phase 2b | 2026-06-01 | rapid, sustained, and clinically meaningful reductions in pruritus Read More | Mirum Pharmaceuticals Announces New Data from Rare Liver Disease Programs Presented at the EASL International Liver Congress 2026 Read More |
Inside Trades
YEARLY INSIDER TRANSACTIONS
Sector Avg.
INSIDERS
SOLDINSIDERS
BOUGHT
SOLDINSIDERS
BOUGHT
POSITIVE SENTIMENT Based on 22 Insiders Transactions
Hedge Funds
Shares Held
HEDGE FUNDS
SOLDHEDGE FUNDS
BOUGHT
SOLDHEDGE FUNDS
BOUGHT
POSITIVE SENTIMENT Based on 27 hedge funds in the last quarter
18 buying (3 new)·9 selling (1 exited)·2 unchanged
Hedge Funds invested in MIRM
| HedgeFund Name ( 3 ) | % of Portfolio | Current MV - | Shares Owned - | Activity Avg Price $0 |
|---|---|---|---|---|
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K |
MIRM Institutional Ownership Trends
Current Insider %
5.20%
—+0.00%
Current Institutional %
62.40%
—+0.00%
Total Ownership
67.60%
Insider + Institutional
Data Points
1
1 Ticker(s)
Option Chain Statistics
| Expiration | Volume | Open Interest | Implied Volatility Calls | Implied Volatility Puts | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Calls | Puts | Put-Call Ratio | Calls | Puts | Put-Call Ratio | IV | OiWaIv | VWaIv | IV | OiWaIv | VWaIv | |
| 2026-10-16 | 0 | 0.00 | 0 | 0 | - | - | - | - | - | - | ||
| 2026-10-16 | 0 | 0.00 | 0 | 0 | - | - | - | - | - | - | ||
| 2026-10-16 | 0 | 0.00 | 0 | 0 | - | - | - | - | - | - | ||
Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last Price | Volume | Open Interest | Last Price | Volume | Open Interest | |
| No data available | ||||||
Open interest
Today's Open Interest
1.00 M
Put-Call Ratio
1.1
Put Open Interest
480.00 K
Call Open Interest
520.00 K
Open Interest Avg (30-day)
900,000
Today vs Open Interest Avg (30-day)
11.11%
Option Volume
Today's Volume
750.00 K
Put-Call Ratio
0.95
Put Volume
360.00 K
Call Volume
390.00 K
Volume Avg (30-day)
800,000
Today vs Volume Avg (30-day)
-6.25%
Company News
MIRMMirum Pharmaceuticals and Incyte Announce Positive Pivotal Phase 2 Results from PROGRESS Study of Zilurgisertib in Fibrodysplasia Ossificans Progressiva
Mirum Pharmaceuticals and Incyte have announced positive results from the pivotal Phase 2 PROGRESS study of Zilurgisertib, a treatment for Fibrodysplasia Ossificans Progressiva (FOP). The study's findings indicate potential benefits for patients suffering from this rare condition. This development could pave the way for further advancements in treatment options.
Read more →MIRMMirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Mirum Pharmaceuticals has reported inducement grants in accordance with Nasdaq Listing Rule 5635(c)(4). The details of these grants were not specified in the announcement. This move is part of the company's compliance with regulatory requirements.
Read more →MIRM▼ -5.1%on this news
Mirum Pharmaceuticals Announces New Data from Rare Liver Disease Programs Presented at the EASL International Liver Congress 2026
Mirum Pharmaceuticals presented new data at the EASL International Liver Congress 2026, showcasing promising results from its rare liver disease programs. The Phase 2b VISTAS study indicated that volixibat significantly reduces pruritus in primary sclerosing cholangitis (PSC). Additionally, the AZURE-1 study demonstrated the efficacy and safety of brelovitug for chronic hepatitis delta virus (HDV). LIVMARLI also showed improved event-free survival in patients with progressive familial intrahepatic cholestasis (PFIC).
Read more →MIRMMirum Pharmaceuticals Announces Proposed Convertible Senior Notes Offering
Mirum Pharmaceuticals announced a proposed offering of $600 million in convertible senior notes due 2032. The offering, aimed at qualified institutional buyers, is subject to market conditions. Proceeds will be used for general corporate purposes, including potential acquisitions and to exchange existing convertible notes. The company focuses on rare diseases and has a strong pipeline of investigational medicines.
Read more →MIRMMirum Pharmaceuticals Prices $600.0 Million Convertible Senior Notes Offering; Refinances a Portion of 2029 Convertible Notes
Mirum Pharmaceuticals has announced the pricing of a $600 million offering of convertible senior notes due in 2032. The company plans to use the proceeds for general corporate purposes, including the acquisition of complementary products and technologies. Additionally, Mirum will exchange a portion of the proceeds to refinance existing convertible notes due in 2029.
Read more →MIRMMirum Pharmaceuticals Reports First Quarter 2026 Financial Results and Provides Business Update - Q1 2026 net product sales of $159.9 million - 2026 net product sales guidance increased to $660 to $680 million - Volixiba
Mirum Pharmaceuticals has reported strong financial results for the first quarter of 2026, with net product sales of $159.9 million and an increase in full-year sales guidance to $660-$680 million. Key highlights include successful Phase 2b study results for Volixibat and Brelovitug, alongside the in-licensing of zilurgisertib, which has received FDA Priority Review. The company remains optimistic about its growth trajectory and ongoing development in the rare disease space. A conference call is scheduled for further business updates.
Read more →MIRM▲ +9.6%on this newsshared move
Mirum Pharmaceuticals to Host Investor Call to Share Topline Results from the VISTAS Study of Volixibat in Patients with Primary Sclerosing Cholangitis on May 4, 2026
Mirum Pharmaceuticals will host an investor call on May 4, 2026, to discuss topline results from the VISTAS study of volixibat for primary sclerosing cholangitis. The call will take place at 8:30 a.m. ET and will be accessible via phone and webcast. Mirum is known for its commitment to developing treatments for rare diseases.
Read more →MIRMMirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - April 13, 2026
Mirum Pharmaceuticals announced the granting of inducement awards to 12 new employees, consisting of stock options and restricted stock units. These awards are part of the company's 2020 Inducement Plan and are intended to attract talent in line with Nasdaq Listing Rule 5635(c)(4). The stock options have an exercise price equal to the closing price on the grant date and will vest over four years.
Read more →MIRMMirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - March 12, 2026
Mirum Pharmaceuticals announced the granting of inducement awards to five new employees, consisting of stock options and restricted stock units. These awards are part of Mirum's 2020 Inducement Plan and are intended to attract talent in line with Nasdaq Listing Rule 5635(c)(4). The stock options will vest over four years, while the RSUs will vest over three years.
Read more →MIRM▼ -5.6%on this news
Mirum Pharmaceuticals Provides AZURE Clinical Program Update for brelovitug in Chronic Hepatitis Delta Virus
Mirum Pharmaceuticals has completed enrollment in the Phase 3 AZURE-1 study and screening in the AZURE-4 study for brelovitug, targeting chronic hepatitis delta virus (HDV). Topline results are anticipated in the second half of 2026, which will support a U.S. BLA submission. Brelovitug has received Breakthrough Therapy designation from the FDA, highlighting its potential in treating this severe viral infection.
Read more →MIRM▼ -15.1%on this news
Mirum Pharmaceuticals Reports Fourth Quarter and Year-End 2025 Results and Provides Business Update
Mirum Pharmaceuticals reported strong financial results for 2025, with net product sales reaching $521 million. The company anticipates continued growth in 2026, projecting sales between $630 million and $650 million. Key clinical milestones are expected in the coming year, including topline data from several pivotal studies. The CEO emphasized the company's commitment to delivering value for shareholders and patients.
Read more →MIRMMirum Pharmaceuticals to Participate in Upcoming March 2026 Investor Conferences
Mirum Pharmaceuticals announced its participation in upcoming investor conferences in March 2026. The company is recognized for its focus on rare diseases and has a robust pipeline of investigational medicines. Live webcasts of the fireside chats will be available, along with archived replays. Mirum's commitment to advancing treatments for overlooked conditions is evident in its strategic development efforts.
Read more →MIRMMirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - February 11, 2026
Mirum Pharmaceuticals announced the granting of inducement awards to 37 new employees, including stock options, restricted stock units, and performance stock units. These awards are part of Mirum's 2020 Inducement Plan and are intended to incentivize new hires. The stock options will vest over four years, while the RSUs and PSUs have specific vesting conditions tied to continued employment and performance metrics.
Read more →MIRM▼ -5.5%on this news
Mirum Pharmaceuticals Announces Health Canada Authorization of LIVMARLI® Tablet Formulation for the Treatment of Cholestatic Pruritus in Patients with Alagille Syndrome
Mirum Pharmaceuticals has received Health Canada authorization for the tablet formulation of LIVMARLI (maralixibat) to treat cholestatic pruritus in patients with Alagille syndrome. This new option complements the existing oral solution, providing greater dosing flexibility for patients as they age. The tablet is intended for patients weighing 22 kg or more who can swallow tablets, enhancing treatment adherence.
Read more →MIRM▼ -5.5%on this newsshared move
Mirum Pharmaceuticals Announces Health Canada Authorization of LIVMARLI® for the Treatment of Cholestatic Pruritus in Patients with Progressive Familial Intrahepatic Cholestasis (PFIC)
Mirum Pharmaceuticals has received Health Canada authorization for LIVMARLI, an oral solution and tablet formulation, to treat cholestatic pruritus in patients aged 12 months or older with progressive familial intrahepatic cholestasis (PFIC). This authorization is based on data from the Phase 3 MARCH study, which demonstrated significant efficacy in reducing pruritus severity. LIVMARLI is expected to improve the quality of life for patients suffering from this rare liver disease.
Read more →MIRMMirum Pharmaceuticals Completes Acquisition of Bluejay Therapeutics, Expanding Global Leadership in Rare Disease
Mirum Pharmaceuticals has completed the acquisition of Bluejay Therapeutics, adding brelovitug, a monoclonal antibody for chronic hepatitis delta virus (HDV), to its portfolio. This acquisition positions Mirum to leverage its expertise in rare diseases and prepare for potential regulatory submissions. The AZURE Phase 3 program for brelovitug is underway, with topline results anticipated in late 2026.
Read more →MIRMMirum Pharmaceuticals Announces Preliminary Unaudited 2025 Results, Demonstrating Strong Commercial Growth and Pipeline Momentum
Mirum Pharmaceuticals announced preliminary unaudited net product sales of about $520 million for 2025, surpassing expectations. The company anticipates 2026 sales to range between $630 million and $650 million. Key upcoming milestones include topline data from the VISTAS study in Q2 2026 and the EXPAND study in Q4 2026. The proposed acquisition of Bluejay Therapeutics aims to bolster their pipeline with brelovitug for chronic hepatitis delta virus.
Read more →MIRMMirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - January 12, 2026
Mirum Pharmaceuticals announced inducement grants for five new employees, consisting of stock options and restricted stock units under its 2020 Inducement Plan. The stock options are priced at $86.57 per share and will vest over four years, while the RSUs will vest over three years. This move aligns with Nasdaq Listing Rule 5635(c)(4) and aims to enhance talent acquisition.
Read more →MIRMMirum Pharmaceuticals Announces Additional Private Placement Financing With TCGX
Mirum Pharmaceuticals has announced a private placement of 1,000,000 shares priced at $68.48 each, raising about $68.5 million. This funding, along with a previous $200 million placement, is intended to support clinical development and the acquisition of Bluejay Therapeutics, pending regulatory approval. Both transactions are expected to close in early 2026.
Read more →MIRM▲ +10.6%on this newsshared move
Mirum Pharmaceuticals Announces Additional Private Placement Financing with TCGx FOSTER CITY, Calif .
Mirum Pharmaceuticals has announced a private placement financing agreement with TCGx, raising approximately $68.5 million through the sale of 1,000,000 shares at $68.48 each. This funding, in addition to a previous $200 million placement, aims to support the company's clinical development and the acquisition of Bluejay Therapeutics. Both transactions are expected to be finalized in early 2026, pending regulatory approval. Mirum's diverse pipeline focuses on rare diseases, highlighting the company's strategic growth initiatives.
Read more →MIRMMirum Pharmaceuticals Enters into Definitive Agreement to Acquire Bluejay Therapeutics, Expanding Global Leadership in Rare Disease -Planned acquisition of brelovitug for chronic hepatitis delta virus (HDV) with Breakthr
Mirum Pharmaceuticals has announced a definitive agreement to acquire Bluejay Therapeutics, enhancing its leadership in rare liver disease treatments. The acquisition focuses on brelovitug, which targets chronic hepatitis delta virus (HDV), a condition lacking FDA-approved therapies. Mirum aims to leverage its expertise in rare liver disorders to advance brelovitug, with Phase 3 data expected in the second half of 2026. The agreement is valued at $250 million in cash and $370 million in stock, plus potential milestone payments.
Read more →MIRMMirum Pharmaceuticals Announces First Patient Enrolled in the BLOOM Phase 2 Clinical Study Evaluating MRM-3379 in Fragile X Syndrome
Mirum Pharmaceuticals has announced the enrollment of the first participant in the BLOOM Phase 2 clinical study for MRM-3379, targeting Fragile X syndrome. This study aims to evaluate the safety and potential benefits of MRM-3379, which has shown promise in preclinical models. Currently, there are no approved therapies for this condition, highlighting the significance of this research.
Read more →MIRMMirum Pharmaceuticals Reports Third Quarter 2025 Financial Results and Provides Business Update - Third quarter 2025 total revenue of $133 million - 2025 revenue guidance updated to $500 to $510 million - Phase 2b VISTAS
Mirum Pharmaceuticals has announced its financial results for the third quarter of 2025, reporting total revenue of $133 million and updating its revenue guidance for the year to between $500 and $510 million. The company highlighted strong commercial performance, particularly with LIVMARLI sales, which grew by 56% year-over-year. Additionally, Mirum provided updates on its clinical pipeline, including completed enrollment for the Phase 2b VISTAS study with topline data expected in mid-2026. Despite these positives, the increase in operating expenses raises concerns regarding financial efficiency.
Read more →MIRMMirum Pharmaceuticals Reports Second Quarter 2025 Financial Results and Provides Business Update - Second quarter 2025 total revenue of $128 million - 2025 revenue guidance increased to $490 to $510 million - Conference
Mirum Pharmaceuticals reported its second quarter 2025 financial results, achieving a total revenue of $128 million, which exhibits substantial growth compared to the previous year. The company raised its revenue guidance for the year to between $490 and $510 million, bolstered by a strong performance in their commercial programs, especially from the LIVMARLI launch. The CEO highlighted the positive momentum with LIVMARLI and upcoming clinical milestones expected in 2026, reaffirming confidence in their product pipeline despite rising operating expenses.
Read more →MIRMMirum Pharmaceuticals Reports First Quarter 2025 Financial Results and Provides Business Update - First quarter 2025 total revenue of $111.6 million 2025 guidance increased to $435 to $450 million - VISTAS study in PSC e
Mirum Pharmaceuticals reported strong financial results for the first quarter of 2025, with total revenue of $111.6 million and a raised revenue guidance for the year to between $435 and $450 million. The FDA approved LIVMARLI's oral tablet formulation, increasing treatment options for patients. Additionally, the company aims to complete enrollment of its VISTAS study by Q3 2025, with topline data anticipated in Q2 2026. Alongside this growth, however, the company also reported increased operating expenses, leading to concerns about future profitability.
Read more →MIRMMirum Pharmaceuticals Reports Fourth Quarter and Year-End 2024 Financial Results and Provides Business Update 2024 net product sales of $336.4 million 2025 expected global net product sales of $420 million to $435 millio
Mirum Pharmaceuticals has announced its financial results for the fourth quarter and year-end 2024, reporting net product sales of $336.4 million. The company anticipates continued growth, projecting global net product sales between $420 million and $435 million for 2025. Key upcoming milestones include the completion of enrollment for the VISTAS study of volixibat in primary sclerosing cholangitis (PSC) expected in the second half of 2025, with topline data anticipated in 2026. Positive interim results from the VANTAGE study for primary biliary cholangitis (PBC) were also highlighted, along with regulatory achievements for their products.
Read more →MIRM▲ +6.5%on this news
Mirum Pharmaceuticals Announces Preliminary Unaudited 2024 Net Product Sales and Cash Balance and Provides Corporate Updates - 2024 net product sales of approximately $336 million exceeds upper end of guidance range prel
Mirum Pharmaceuticals announced preliminary unaudited net product sales for 2024, reaching approximately $336 million, exceeding prior guidance. The company also provided an optimistic outlook for 2025, projecting sales between $420 million and $435 million. Notable advancements include positive interim results for its volixibat studies and a successful NDA submission for chenodiol. However, the reported figures are preliminary and subject to verification.
Read more →MIRMMirum Pharmaceuticals Reports Third Quarter 2024 Financial Results and Provides Business Update Third quarter global net product sales of $90.3 million, 2024 guidance increased to $330-335 million Volixibat granted break
Mirum Pharmaceuticals reported a significant increase in third quarter 2024 global net product sales, reaching $90.3 million, a 89% increase from the previous year. The company also provided an updated guidance for 2024, increasing its expected sales to $330-335 million. Notably, volixibat received breakthrough therapy designation for treating cholestatic pruritus in PBC, and interim results from a related study will be presented at The Liver Meeting 2024. Additionally, Mirum has announced a PDUFA date for chenodiol in CTX on December 28, 2024, and in-licensed a PDE4D inhibitor for Fragile X syndrome, reinforcing its commitment to rare disease treatment development.
Read more →MIRMMirum Pharmaceuticals Reports Second Quarter 2024 Financial Results and Provides Business Update Second quarter global net product sales of $77.8 million, on track to achieve full-year guidance of $310 to $320 million Po
Mirum Pharmaceuticals reported strong financial results for the second quarter of 2024, with global net product sales of $77.8 million, reflecting substantial year-over-year growth. The company highlighted positive interim results for volixibat in the VISTAS PSC and VANTAGE PBC studies, indicating potential advancements in treatment for rare liver diseases. Regulatory achievements included marketing authorization for LIVMARLI in Europe for patients with PFIC. Additionally, the initiation of the LIVMARLI EXPAND study aims to explore further applications of the drug in cholestatic conditions.
Read more →MIRMMirum Pharmaceuticals Reports First Quarter 2024 Financial Results and Provides Business Update First quarter 2024 total revenue of $69.2 million, on track to achieve full-year guidance of $310 to $320 million FDA approv
Mirum Pharmaceuticals has reported a total revenue of $69.2 million for the first quarter of 2024, with expectations to meet its full-year guidance of $310 to $320 million. The company's FDA approval of LIVMARLI for cholestatic pruritus in PFIC patients marks a key achievement. The firm also noted a substantial cash balance of $302.8 million and highlighted ongoing developments in its drug pipeline, including upcoming interim analyses for volixibat studies. However, there are rising operating expenses and associated risks concerning product acceptance due to potential side effects.
Read more →MIRMMirum Pharmaceuticals Reports Fourth Quarter and Year-End 2023 Financial Results and Provides Business Update - Net product sales totaled $178.9 million, and full year 2023 revenue totaled $186.4 million, delivering 142%
Mirum Pharmaceuticals reported strong financial results for the fourth quarter and year-end 2023, with net product sales totaling $178.9 million and a remarkable 142% year-over-year revenue increase. The company anticipates global net product sales to reach between $310 million and $320 million in 2024, bolstered by the growth of its drug LIVMARLI. Additionally, key upcoming regulatory milestones include a PDUFA date for LIVMARLI in progressive familial intrahepatic cholestasis, set for March 13, 2024. Despite the positive financial outlook, the company has seen a rise in operating expenses and must continue to monitor the safety profiles of its products.
Read more →MIRMMirum Pharmaceuticals Announces Preliminary Unaudited 2023 Net Revenue and Provides Corporate Updates - $186-188 million in total revenue and $178-180 million net product sales expected for 2023, preliminary and unaudite
Mirum Pharmaceuticals has announced preliminary unaudited revenue estimates for 2023, expecting total revenue between $186-188 million and net product sales of $178-180 million. The year was described as transformative for the company, with significant advancements and strong global adoption of their products, particularly LIVMARLI. The CEO expressed optimism about growth prospects and expansion opportunities for their medicines, as well as plans for a company presentation at the J.P. Morgan Healthcare Conference in January 2024.
Read more →MIRMMirum Pharmaceuticals Reports Third Quarter 2023 Financial Results and Provides Business Update - Third quarter 2023 total revenue of $47.7 million - Completed acquisition of CHENODAL and CHOLBAM - Announced positive Pha
Mirum Pharmaceuticals reported a significant increase in total revenue for Q3 2023, reaching $47.7 million, compared to $18.8 million for the same quarter in 2022. The company completed the acquisition of CHENODAL and CHOLBAM, enhancing its offerings in pediatric hepatology. Notably, positive data from the Phase 3 RESTORE study of CHENODAL for CTX was announced, with an NDA filing expected in the first half of 2024. LIVMARLI continues to see robust growth in sales, particularly in the treatment of Alagille syndrome and PFIC, supported by ongoing clinical studies and an impending sNDA review for label expansion.
Read more →MIRMrefer to Mirum Pharmaceuticals, Inc. SUMMARY OF RISKS ASSOCIATED WITH OUR BUSINESS An investment in shares of our common stock involves a high degree of risk. Below is a list of the more significant risks associated with
Mirum Pharmaceuticals, Inc. has outlined significant risks linked to its business operations and investments in shares of its common stock. The company highlights the challenges in successfully commercializing its products, namely Livmarli, Chenodal, and Cholbam. Moreover, it points out potential issues related to securing adequate coverage and reimbursement from payors. The competition for hiring skilled sales and marketing professionals may also hinder its growth and financial performance.
Read more →MIRMMirum Pharmaceuticals Completes Acquisition of Bile Acid Product Portfolio for Treatment of Rare Liver Diseases from Travere Therapeutics Mirum has acquired Travere s rights and assets related to Cholbam and Chenodal Tra
Mirum Pharmaceuticals has completed its acquisition of Travere Therapeutics' bile acid product portfolio, which includes Cholbam and Chenodal, aimed at treating rare liver diseases. The deal involved an upfront payment of $210 million, along with up to $235 million in potential sales-based milestones for Travere. This acquisition strengthens Mirum's market position and opens up opportunities for a near-term Phase 3 label expansion. The closing of the deal was subject to customary conditions, and Travere will provide transitional services to Mirum post-acquisition.
Read more →MIRMMirum Pharmaceuticals Reports Second Quarter 2023 Financial Results and Provides Business Update - $37.5 million total revenue, including net product sales for LIVMARLI (maralixibat) oral solution of $32.5 million, for s
Mirum Pharmaceuticals reported strong financial results for the second quarter of 2023, with total revenue of $37.5 million, up 86% from the previous year. The company is advancing its pediatric hepatology franchise through the acquisition of CHENODAL and CHOLBAM, expected to significantly boost annual sales. Additionally, Mirum anticipates multiple late-stage clinical trial data readouts in the second half of this year, further enhancing its therapeutic offerings in rare liver diseases. LIVMARLI, its flagship product, continues to see increased adoption and sales growth, particularly for Alagille syndrome.
Read more →MIRMMirum Pharmaceuticals Enters Agreement to Acquire Bile Acid Product Portfolio for the Treatment of Rare Liver Diseases from Travere Therapeutics Mirum to acquire all of Travere s rights and assets related to Cholbam and
Mirum Pharmaceuticals has announced a definitive agreement to acquire the bile acid product portfolio from Travere Therapeutics for $445 million. This includes the medications Cholbam and Chenodal, aimed at treating rare liver diseases. The acquisition, expected to close in the third quarter of 2023, will be funded through a private placement that has already raised $210 million. Mirum's president stated that this will enhance their position in pediatric hepatology and contribute to advancing treatment options for patients with rare liver conditions.
Read more →MIRMMirum Pharmaceuticals Reports First Quarter 2023 Financial Results and Provides Business Update - $31.6 million total revenue, including net product sales for LIVMARLI (maralixibat) oral solution of $29.1 million, for fi
Mirum Pharmaceuticals reported its financial results for Q1 2023, showcasing strong performance with total revenue of $31.6 million, primarily driven by net product sales of LIVMARLI. The company highlighted a 167% increase in net sales compared to the same quarter last year and recent FDA label expansion for LIVMARLI targeting younger patients. Additionally, Mirum has multiple milestones expected later in 2023, supporting its growth in the rare liver disease market. Despite rising operating expenses, the company maintains a solid financial position with $232.1 million in cash and equivalents.
Read more →MIRM▼ -5.9%on this news
Mirum Pharmaceuticals Announces Proposed Convertible Senior Notes Offering FOSTER CITY, Calif. (BUSINESS WIRE)
Mirum Pharmaceuticals announced plans to offer $200 million in convertible senior notes due 2029 in a private placement directed at qualified institutional buyers. The proceeds from this offering are intended for repurchasing revenue interests and supporting corporate expenses. Noteholders will have options regarding the convertibility and redemption of the notes under defined conditions. This strategic financial maneuver reflects Mirum's commitment to managing its capital structure and advancing its business objectives, though market conditions could impact the offering's success.
Read more →MIRM▼ -5.9%on this news
Mirum Pharmaceuticals Announces Preliminary Unaudited First Quarter 2023 Financial Results
Mirum Pharmaceuticals announced preliminary unaudited financial results for the first quarter of 2023, highlighting estimated revenue and cash balance. The company has also provided updates on its VISTAS Phase 2b clinical trial for volixibat and the VANTAGE study, both expected to release interim analyses in the latter half of 2023. Additionally, there are ongoing clinical evaluations for LIVMARLI across various indications. However, these financial results are preliminary and could change as the company completes its financial closure processes.
Read more →MIRMMirum Pharmaceuticals Reports Fourth Quarter and Year-End 2022 Financial Results and Provides Business Update - Net product sales for LIVMARLI (maralixibat) oral solution totaled $75.1 million for first full fiscal year
Mirum Pharmaceuticals reported robust financial results for the fourth quarter and year-end 2022, with net product sales of $75.1 million for LIVMARLI after its U.S. launch. The company's overall revenue for 2022 reached $77.1 million, and it anticipates a significant 50% growth in net sales for the upcoming year. Key developments included successful clinical outcomes for LIVMARLI in treating Alagille syndrome and progressive familial intrahepatic cholestasis, along with a strategic launch in Germany. The company is also focused on furthering its pipeline with late-stage studies in rare liver diseases.
Read more →MIRMMirum Pharmaceuticals Announces Preliminary Unaudited LIVMARLI 2022 Net Revenue and Provides Corporate Updates - $76 million in total revenue and $74 million net product sales anticipated for LIVMARLI for 2022, prelimina
Mirum Pharmaceuticals has announced preliminary unaudited revenue figures for 2022, forecasting $76 million in total revenue with $74 million coming from net product sales of its drug LIVMARLI. The company is also planning a supplemental New Drug Application (sNDA) submission for LIVMARLI in progressive familial intrahepatic cholestasis (PFIC) in early 2023. With the intention of achieving a 50% growth in net sales in the U.S. for 2023, Mirum is focusing on expanding their pipeline and preparing for a presentation at the J.P. Morgan Healthcare Conference. However, the company faces uncertainties as their financial results are preliminary and the CFO is due to depart soon.
Read more →MIRM▼ -16.4%on this news
Mirum Pharmaceuticals Reports Third Quarter 2022 Financial Results and Provides Business Update - Net product sales for LIVMARLI (maralixibat) oral solution totaled $18.8 million in the third quarter of 2022 and $47.2 mi
Mirum Pharmaceuticals Reports Third Quarter 2022 Financial Results and Provides Business Update - Net product sales for LIVMARLI (maralixibat) oral solution totaled $18.8 million in the third quarter of 2022 and $47.2 million year-to-date - Mirum raises 2022 full year net produ
Read more →MIRMPositive Topline Data Announced from Mirum s LIVMARLI Phase 3 MARCH Study in Progressive Familial Intrahepatic Cholestasis (PFIC) Met primary endpoint (p=0.0098); highly statistically significant effects in all PFIC subt
Positive Topline Data Announced from Mirum s LIVMARLI Phase 3 MARCH Study in Progressive Familial Intrahepatic Cholestasis (PFIC) FOSTER CITY, Calif. OCTOBER 24, 2022 - Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM), today announced positive topline results from its pivotal Phase
Read more →MIRM▲ +11.8%on this news· ran to +26% by day 1
Mirum Pharmaceuticals Reports Second Quarter 2022 Financial Results and Provides Business Update - Net product sales for LIVMARLI (maralixibat) oral solution totaled $17.5 million in the second quarter of 2022 and $28.4
Mirum Pharmaceuticals Reports Second Quarter 2022 Financial Results and Provides Business Update - Net product sales for LIVMARLI (maralixibat) oral solution totaled $17.5 million in the second quarter of 2022 and $28.4 million year-to-date - Conference call to provide business
Read more →MIRMMirum Pharmaceuticals Appoints Saira Ramasastry to Board of Directors
Mirum Pharmaceuticals Appoints Saira Ramasastry to Board of Directors FOSTER CITY, Calif. June 6, 2022 - Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM) today announced the appointment of Saira Ramasastry to the Company s board of directors and as a member of the audit committee whe
Read more →MIRM▲ +6.1%on this news
Mirum Pharmaceuticals Reports First Quarter 2022 Financial Results and Provides Business Update - Total revenue for the first quarter of 2022 was $12.9 million including net product revenue for LIVMARLI (maralixibat) ora
Mirum Pharmaceuticals Reports First Quarter 2022 Financial Results and Provides Business Update - Total revenue for the first quarter of 2022 was $12.9 million including net product revenue for LIVMARLI (maralixibat) oral solution of $10.9 million. - Conference call to provide
Read more →MIRM▲ +7.5%on this news
Mirum Pharmaceuticals Reports Fourth Quarter and Year-End 2021 Financial Results and Provides Business Update - Strong commercial launch underway with LIVMARLI (maralixibat) oral solution; net product revenue of $3.1 mil
Mirum Pharmaceuticals Reports Fourth Quarter and Year-End 2021 Financial Results and Provides Business Update - Strong commercial launch underway with LIVMARLI (maralixibat) oral solution; net product revenue of $3.1 million for the first quarter of launch, total 2021 company re
Read more →MIRMMirum Pharmaceuticals Provides Business Update and Highlights Key 2022 Corporate Milestones Unaudited estimated total LIVMARLI net product revenue of $3.0 million for fourth quarter 2021. Preliminary cash, cash equivalen
Mirum Pharmaceuticals Provides Business Update and Highlights Key 2022 Corporate Milestones FOSTER CITY, CA January 11, 2022 Mirum Pharmaceuticals, Inc. (NASDAQ: MIRM) today provided a corporate update and highlighted key 2022 milestones in conjunction with its presentation at
Read more →MIRMMirum Pharmaceuticals Reports Third Quarter 2021 Financial Results and Provides Business Update - U.S. commercial launch underway following U.S. FDA approval of LIVMARLI TM (maralixibat) oral solution - Six-year analysis
Mirum Pharmaceuticals Reports Third Quarter 2021 Financial Results and Provides Business Update -U.S. commercial launch underway following U.S. FDA approval of LIVMARLITM (maralixibat) oral solution -Six-year analysis showing significant improvement in event-free survival with
Read more →MIRMU.S. FDA Approves LIVMARLI (maralixibat) as the First and Only Approved Medication for the Treatment of Cholestatic Pruritus in Patients with Alagille Syndrome One Year of Age and Older - Mirum to host an investor call o
U.S. FDA Approves LIVMARLI (maralixibat) as the First and Only Approved Medication for the Treatment of Cholestatic Pruritus in Patients with Alagille Syndrome One Year of Age and Older - Mirum to host an investor call on September 29, 2021 at 4:30 p.m. ET FOSTER CITY, Calif.
Read more →MIRMMirum Pharmaceuticals Appoints Biotechnology Executive William C. Fairey to its Board of Directors
Mirum Pharmaceuticals Appoints Biotechnology Executive William C. Fairey to its Board of Directors FOSTER CITY, Calif. August 19, 2021 - Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM) today announced the appointment of industry veteran William C. Fairey to its Board of Directors. M
Read more →MIRMMirum Pharmaceuticals Reports Second Quarter 2021 Financial Results and Provides Business Update - NDA for maralixibat for cholestatic pruritus in Alagille syndrome under priority review; PDUFA date is
Mirum Pharmaceuticals Reports Second Quarter 2021 Financial Results and Provides Business Update -NDA for maralixibat for cholestatic pruritus in Alagille syndrome under priority review; PDUFA date is September 29, 2021 -Commercial preparations complete in anticipation of U.S.
Read more →MIRMMirum Pharmaceuticals Appoints Veteran Biotechnology Executive Carol L. Brosgart, M.D. to Board of Directors
Mirum Pharmaceuticals Appoints Veteran Biotechnology Executive Carol L. Brosgart, M.D. to Board of FOSTER CITY, Calif. June 7, 2021 - Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM) today announced the appointment of Carol L. Brosgart, M.D., clinical professor of medicine, biostatis
Read more →MIRMMirum Pharmaceuticals Reports First Quarter 2021 Financial Results and Provides Business Update - NDA for maralixibat in Alagille syndrome (ALGS) granted priority review by U.S. FDA; PDUFA date is
Mirum Pharmaceuticals Reports First Quarter 2021 Financial Results and Provides Business Update FOSTER CITY, Calif. - May 6, 2021 - Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM), today reported financial results for the quarter ended March 31, 2021 and provided a business update.
Read more →MIRMMirum Pharmaceuticals Reports Fourth Quarter and Year-End 2020 Results and Provides Business Updates - U.S. launch of maralixibat for Alagille syndrome (ALGS) planned for second half of 2021, if approved by FDA - Phase 2
Mirum Pharmaceuticals Reports Fourth Quarter and Year-End 2020 Results and Provides Business Updates FOSTER CITY, Calif. - March 9, 2021 - Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM), today announced financial results for the fourth quarter and year-end 2020 and provided business
Read more →MIRMMirum Pharmaceuticals Provides Corporate Update - Completion of maralixibat rolling NDA targeted for Q1 2021 - Expecting first-patient-in for volixibat studies in ICP and PSC, and maralixibat study in biliary atresia in
Mirum Pharmaceuticals Provides Corporate Update - Completion of maralixibat rolling NDA targeted for Q1 2021 - Expecting first-patient-in for volixibat studies in ICP and PSC, and maralixibat study in biliary - Launching volixibat primary biliary cholangitis program in H2 2021
Read more →MIRMCertain information in this document identified by brackets has been omitted because it is both not material and would be competitively harmful if publicly disclosed. Execution Version REVENUE INTEREST PURCHASE AGREEMENT
Certain information in this document identified by brackets has been omitted because it is both not material and would be competitively harmful if publicly disclosed. REVENUE INTEREST PURCHASE AGREEMENT dated as of December 8, 2020 MIRUM PHARMACEUTICALS, INC., the Purchasers
Read more →MIRMMirum Pharmaceuticals Provides Third Quarter 2020 Financial Results and Business Update, and Announces Virtual Investor Day - Initiated rolling NDA submission and launched Expanded Access Program for maralixibat in Alagi
Mirum Pharmaceuticals Provides Third Quarter 2020 Financial Results and Business Update, and Announces Virtual Investor Day FOSTER CITY, Calif. - November 12, 2020 - Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM), a biopharmaceutical company focused on the development and commercial
Read more →MIRMMirum Pharmaceuticals Announces Second Quarter 2020 Financial Results and Provides Clinical Program Updates - Rolling NDA submission for maralixibat in Alagille syndrome (ALGS) to be initiated in third quarter 2020; plan
Mirum Pharmaceuticals Announces Second Quarter 2020 Financial Results and Provides Clinical Program Updates FOSTER CITY, Calif. - August 6, 2020 - Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM), a biopharmaceutical company focused on the development and commercialization of novel th
Read more →MIRMMirum Pharmaceuticals Reports First Quarter 2020 Financial Results and Provides Business Updates - On track to begin rolling submission of NDA for maralixibat in Alagille Syndrome (ALGS) in third quarter 2020 - Cash, cas
Mirum Pharmaceuticals Reports First Quarter 2020 Financial Results and Provides Business Updates in third quarter 2020 FOSTER CITY, Calif. - May 7, 2020 - Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM), a biopharmaceutical company focused on the development and commercialization of
Read more →MIRMMirum Pharmaceuticals Reports Fourth Quarter and Full Year 2019 Financial Results and Provides Corporate Update New Drug Application Rolling Submission for Alagille Syndrome Planned to Begin in Third Quarter 2020 Cash, C
Mirum Pharmaceuticals Reports Fourth Quarter and Full Year 2019 Financial Results and Provides Corporate Update New Drug Application Rolling Submission for Alagille Syndrome Planned to Begin in Third Quarter 2020 Cash, Cash Equivalents and Investments Balance of $140.0 million
Read more →MIRMMirum Pharmaceuticals Promotes Ian Clements to Chief Financial Officer Foster City, Calif.
Mirum Pharmaceuticals Promotes Ian Clements to Chief Financial Officer Foster City, Calif., January 14, 2020 Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM), a biopharmaceutical company focused on the development and commercialization of novel therapies for debilitating liver diseas
Read more →MIRMMirum Pharmaceuticals Reports Third Quarter Financial Results and Provides Corporate Update Breakthrough Therapy Designation for Maralixibat for the Treatment of Pruritus Associated with Alagille Syndrome Granted Cash, C
Mirum Pharmaceuticals Reports Third Quarter Financial Results and Provides Corporate Update Breakthrough Therapy Designation for Maralixibat for the Treatment of Pruritus Associated with Alagille Syndrome Granted Cash, Cash Equivalents and Investments Balance of $153.6 million
Read more →MIRMMirum Pharmaceuticals Reports Second Quarter Financial Results and Provides Corporate Update
Mirum Pharmaceuticals Reports Second Quarter Financial Results and Provides Corporate Update FOSTER CITY, Calif. August 28, 2019 Mirum Pharmaceuticals, Inc. (NASDAQ: MIRM), a biopharmaceutical company focused on the development and commercialization of a late-stage pipeline of
Read more →Competitive Position
How MIRM ranks across every disease it competes inCompetitive Position is a premium feature
See how MIRM ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trial